Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use LEQEMBI ® safely and effectively. See full prescribing information for LEQEMBI ® . LEQEMBI ® (lecanemab-irmb) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
- generic_name
- lecanemab
- product_names
- lecanemab, lecanemab-irmb
- ndc
- 62856-215, 62856-215-01, 62856-212, 62856-212-01, 62856-220, 62856-220-10, 62856-220-01, 62856-222, 62856-222-10, 62856-222-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en